Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.
Hanrahan AJ, Sylvester BE, Chang MT, Elzein A, Gao J, Han W, Liu Y, Xu D, Gao SP, Gorelick AN, Jones AM, Kiliti AJ, Nissan MH, Nimura CA, Poteshman AN, Yao Z, Gao Y, Hu W, Wise HC, Gavrila EI, Shoushtari AN, Tiwari S, Viale A, Abdel-Wahab O, Merghoub T, Berger MF, Rosen N, Taylor BS, Solit DB. Hanrahan AJ, et al. Among authors: berger mf. Cancer Res. 2020 Oct 1;80(19):4233-4243. doi: 10.1158/0008-5472.CAN-20-0865. Epub 2020 Jul 8. Cancer Res. 2020. PMID: 32641410 Free PMC article.
Genome sequencing identifies a basis for everolimus sensitivity.
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. Iyer G, et al. Among authors: berger mf. Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23. Science. 2012. PMID: 22923433 Free PMC article.
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Catalanotti F, et al. Among authors: berger mf. Clin Cancer Res. 2013 Apr 15;19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444215 Free PMC article. Clinical Trial.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. Nissan MH, et al. Among authors: berger mf. Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27. Cancer Res. 2014. PMID: 24576830 Free PMC article.
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB. Abdel-Wahab O, et al. Among authors: berger mf. Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3. Cancer Discov. 2014. PMID: 24589925 Free PMC article.
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Motzer RJ, Berger MF, Hsieh JJ. Voss MH, et al. Among authors: berger mf. Clin Cancer Res. 2014 Apr 1;20(7):1955-64. doi: 10.1158/1078-0432.CCR-13-2345. Epub 2014 Mar 12. Clin Cancer Res. 2014. PMID: 24622468 Free PMC article.
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, Gao J, Schultz N, Gonen M, Soslow RA, Berger MF, Levine DA. Jelinic P, et al. Among authors: berger mf. Nat Genet. 2014 May;46(5):424-6. doi: 10.1038/ng.2922. Epub 2014 Mar 23. Nat Genet. 2014. PMID: 24658004 Free PMC article.
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O. Chung SS, et al. Among authors: berger mf. Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004. Sci Transl Med. 2014. PMID: 24871132 Free PMC article.
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner BH, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH, Solit DB, Taylor BS. Al-Ahmadie H, et al. Among authors: berger mf. Cancer Discov. 2014 Sep;4(9):1014-21. doi: 10.1158/2159-8290.CD-14-0380. Epub 2014 Jun 16. Cancer Discov. 2014. PMID: 24934408 Free PMC article.
386 results